Serotonin a la carte

Supplementation with the serotonin precursor 5-hydroxytryptophan

Erick Turner, Jennifer Loftis, Aaron D. Blackwell

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

This paper reviews the preclinical and clinical evidence regarding the use of the dietary supplement 5-hydroxytryptophan (5-HTP) for the treatment of depression. In the absence of supplementation with exogenous 5-HTP, the amount of endogenous 5-HTP available for serotonin synthesis depends on the availability of tryptophan and on the activity of various enzymes, especially tryptophan hydroxylase, indoleamine 2,3-dioxygenase, and tryptophan 2,3-dioxygenase (TDO). Factors affecting each of these are reviewed. The amount of 5-HTP reaching the central nervous system (CNS) is affected by the extent to which 5-HTP is converted to serotonin in the periphery. This conversion is controlled by the enzyme amino acid decarboxylase, which, in the periphery, can be blocked by peripheral decarboxylase inhibitors (PDIs) such as carbidopa. Preclinical and clinical evidence for the efficacy of 5-HTP for depression is reviewed, with emphasis on double-blind, placebo-controlled (DB-PC) trials. Safety issues with 5-HTP are also reviewed, with emphasis on eosinophilia myalgia syndrome (EMS) and serotonin syndrome.

Original languageEnglish (US)
Pages (from-to)325-338
Number of pages14
JournalPharmacology and Therapeutics
Volume109
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

5-Hydroxytryptophan
Serotonin
Carboxy-Lyases
Eosinophilia-Myalgia Syndrome
Serotonin Syndrome
Tryptophan Oxygenase
Indoleamine-Pyrrole 2,3,-Dioxygenase
Carbidopa
Tryptophan Hydroxylase
Enzymes
Dietary Supplements
Tryptophan
Central Nervous System
Placebos
Safety
Amino Acids

Keywords

  • 5-HTP
  • Antidepressants
  • Depression
  • Selective serotonin re-uptake inhibitor
  • Serotonin
  • Tryptophan

ASJC Scopus subject areas

  • Pharmacology

Cite this

Serotonin a la carte : Supplementation with the serotonin precursor 5-hydroxytryptophan. / Turner, Erick; Loftis, Jennifer; Blackwell, Aaron D.

In: Pharmacology and Therapeutics, Vol. 109, No. 3, 03.2006, p. 325-338.

Research output: Contribution to journalArticle

@article{a574e6c1a9ac4147b849c7933e9044f0,
title = "Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan",
abstract = "This paper reviews the preclinical and clinical evidence regarding the use of the dietary supplement 5-hydroxytryptophan (5-HTP) for the treatment of depression. In the absence of supplementation with exogenous 5-HTP, the amount of endogenous 5-HTP available for serotonin synthesis depends on the availability of tryptophan and on the activity of various enzymes, especially tryptophan hydroxylase, indoleamine 2,3-dioxygenase, and tryptophan 2,3-dioxygenase (TDO). Factors affecting each of these are reviewed. The amount of 5-HTP reaching the central nervous system (CNS) is affected by the extent to which 5-HTP is converted to serotonin in the periphery. This conversion is controlled by the enzyme amino acid decarboxylase, which, in the periphery, can be blocked by peripheral decarboxylase inhibitors (PDIs) such as carbidopa. Preclinical and clinical evidence for the efficacy of 5-HTP for depression is reviewed, with emphasis on double-blind, placebo-controlled (DB-PC) trials. Safety issues with 5-HTP are also reviewed, with emphasis on eosinophilia myalgia syndrome (EMS) and serotonin syndrome.",
keywords = "5-HTP, Antidepressants, Depression, Selective serotonin re-uptake inhibitor, Serotonin, Tryptophan",
author = "Erick Turner and Jennifer Loftis and Blackwell, {Aaron D.}",
year = "2006",
month = "3",
doi = "10.1016/j.pharmthera.2005.06.004",
language = "English (US)",
volume = "109",
pages = "325--338",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Serotonin a la carte

T2 - Supplementation with the serotonin precursor 5-hydroxytryptophan

AU - Turner, Erick

AU - Loftis, Jennifer

AU - Blackwell, Aaron D.

PY - 2006/3

Y1 - 2006/3

N2 - This paper reviews the preclinical and clinical evidence regarding the use of the dietary supplement 5-hydroxytryptophan (5-HTP) for the treatment of depression. In the absence of supplementation with exogenous 5-HTP, the amount of endogenous 5-HTP available for serotonin synthesis depends on the availability of tryptophan and on the activity of various enzymes, especially tryptophan hydroxylase, indoleamine 2,3-dioxygenase, and tryptophan 2,3-dioxygenase (TDO). Factors affecting each of these are reviewed. The amount of 5-HTP reaching the central nervous system (CNS) is affected by the extent to which 5-HTP is converted to serotonin in the periphery. This conversion is controlled by the enzyme amino acid decarboxylase, which, in the periphery, can be blocked by peripheral decarboxylase inhibitors (PDIs) such as carbidopa. Preclinical and clinical evidence for the efficacy of 5-HTP for depression is reviewed, with emphasis on double-blind, placebo-controlled (DB-PC) trials. Safety issues with 5-HTP are also reviewed, with emphasis on eosinophilia myalgia syndrome (EMS) and serotonin syndrome.

AB - This paper reviews the preclinical and clinical evidence regarding the use of the dietary supplement 5-hydroxytryptophan (5-HTP) for the treatment of depression. In the absence of supplementation with exogenous 5-HTP, the amount of endogenous 5-HTP available for serotonin synthesis depends on the availability of tryptophan and on the activity of various enzymes, especially tryptophan hydroxylase, indoleamine 2,3-dioxygenase, and tryptophan 2,3-dioxygenase (TDO). Factors affecting each of these are reviewed. The amount of 5-HTP reaching the central nervous system (CNS) is affected by the extent to which 5-HTP is converted to serotonin in the periphery. This conversion is controlled by the enzyme amino acid decarboxylase, which, in the periphery, can be blocked by peripheral decarboxylase inhibitors (PDIs) such as carbidopa. Preclinical and clinical evidence for the efficacy of 5-HTP for depression is reviewed, with emphasis on double-blind, placebo-controlled (DB-PC) trials. Safety issues with 5-HTP are also reviewed, with emphasis on eosinophilia myalgia syndrome (EMS) and serotonin syndrome.

KW - 5-HTP

KW - Antidepressants

KW - Depression

KW - Selective serotonin re-uptake inhibitor

KW - Serotonin

KW - Tryptophan

UR - http://www.scopus.com/inward/record.url?scp=31144432056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31144432056&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2005.06.004

DO - 10.1016/j.pharmthera.2005.06.004

M3 - Article

VL - 109

SP - 325

EP - 338

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -